Literature DB >> 20433574

Inverse vaccination, the opposite of Jenner's concept, for therapy of autoimmunity.

L Steinman1.   

Abstract

DNA-based vaccines to induce antigen-specific inhibition of immune responses in human autoimmune diseases represent the inverse of what Jenner intended when he invented vaccination. Jenner's vaccine induced antigen-specific immunity to small pox. DNA vaccines for autoimmunity have been developed in preclinical settings, and now tested in human trials. The first two clinical trials, one in relapsing remitting multiple sclerosis, and the other in type 1 diabetes indicate that specific inhibition of antigen-specific antibody and T-cell responses is attainable in humans. Further development of this approach is ongoing. This new version of immunization termed 'inverse vaccination' when applied to autoimmune diseases, may allow targeted reduction of unwanted antibody and T-cell responses to autoantigens, while leaving the remainder of the immune system intact. The method of specifically reducing a pathological adaptive autoimmune response is termed inverse vaccination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20433574     DOI: 10.1111/j.1365-2796.2010.02224.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  11 in total

1.  The inverse of immunity.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2010-07       Impact factor: 53.440

Review 2.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

3.  Single-cell analysis of glandular T cell receptors in Sjögren's syndrome.

Authors:  Michelle L Joachims; Kerry M Leehan; Christina Lawrence; Richard C Pelikan; Jacen S Moore; Zijian Pan; Astrid Rasmussen; Lida Radfar; David M Lewis; Kiely M Grundahl; Jennifer A Kelly; Graham B Wiley; Mikhail Shugay; Dmitriy M Chudakov; Christopher J Lessard; Donald U Stone; R Hal Scofield; Courtney G Montgomery; Kathy L Sivils; Linda F Thompson; A Darise Farris
Journal:  JCI Insight       Date:  2016-06-02

4.  Optimization of current and future therapy for autoimmune diseases.

Authors:  Lawrence Steinman; Joan T Merrill; Iain B McInnes; Mark Peakman
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

5.  Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis.

Authors:  Mark D Mannie; J Lori Blanchfield; S M Touhidul Islam; Derek J Abbott
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

6.  Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk.

Authors:  Janka Mátrai; Alessio Cantore; Cynthia C Bartholomae; Andrea Annoni; Wei Wang; Abel Acosta-Sanchez; Ermira Samara-Kuko; Liesbeth De Waele; Ling Ma; Pietro Genovese; Martina Damo; Anne Arens; Kevin Goudy; Timothy C Nichols; Christof von Kalle; Marinee K L Chuah; Maria Grazia Roncarolo; Manfred Schmidt; Thierry Vandendriessche; Luigi Naldini
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

Review 7.  Restoring immune tolerance in neuromyelitis optica: Part I.

Authors:  Larry Steinman; Amit Bar-Or; Jacinta M Behne; Daniel Benitez-Ribas; Peter S Chin; Michael Clare-Salzler; Donald Healey; James I Kim; David M Kranz; Andreas Lutterotti; Roland Martin; Sven Schippling; Pablo Villoslada; Cheng-Hong Wei; Howard L Weiner; Scott S Zamvil; Michael R Yeaman; Terry J Smith
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-09-07

Review 8.  Engineering self-assembled materials to study and direct immune function.

Authors:  Lisa H Tostanoski; Christopher M Jewell
Journal:  Adv Drug Deliv Rev       Date:  2017-04-06       Impact factor: 15.470

9.  Tolerogenic Immunomodulation by PEGylated Antigenic Peptides.

Authors:  Jennifer Pfeil; Mario Simonetti; Uta Lauer; Rudolf Volkmer; Bianca von Thülen; Pawel Durek; Ralf Krähmer; Frank Leenders; Alf Hamann; Ute Hoffmann
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

10.  Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy.

Authors:  Peggy P Ho; Lauren J Lahey; Foteini Mourkioti; Peggy E Kraft; Antonio Filareto; Moritz Brandt; Klas E G Magnusson; Eric E Finn; Jeffrey S Chamberlain; William H Robinson; Helen M Blau; Lawrence Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-04       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.